Advertisement

Chromatographia

, Volume 56, Issue 1, pp S181–S184 | Cite as

Determination of methylparaben, propylparaben, clotrimazole and its degradation products in topical cream by RP-HPLC

  • P. Solich
  • R. Hájková
  • M. Pospíšilová
  • J. Šícha
Short Communications Column Liquid Chromatography

Summary

Reversed-phase, high-performance liquid chromatographic (RP-HPLC) methods with UV detection were developed and validated for determination of compounds in a topical cream. The first method describes determination of the active component clotrimazole and two preservatives present in the cream; methylparaben and propylparaben. The second method describes determination of two degradation products of clotrimazole, imidazole and (2-chlorophenyl) diphenylmethanol, in a topical cream after long-term stability tests.

Chromatographic separation was on a Purospher RP-18e column; the mobile phase in Method1 for separation of clotrimazole, methylparaben and propylparaben comprises acetonitrile and water (70:30 v/v). For determination of degradations products-imidazole and (2-chlorophenyl) diphenylmethanol—the optimum composition of mobile phase in Method2 was acetonitrile and water (75:25 v/v) apparent pH* 2.7. Analysis time was <10 min for both methods. The methods were found to be applicable for routine analysis of the active compound clotrimazole, preservatives and degradation products in the pharmaceutical product: topical cream 1% Clotrimazol Cream.

Key Words

Column liquid chromatography Pharmaceuticals Degradation products Methylparaben Propylparaben Clotrimazol 

References

  1. [1]
    Valenta, C.; Lecer, A.; Spiegl, P.Pharmazie 1992,47 (8), 641–642.Google Scholar
  2. [2]
    Hoogerheide, J.C.; Strusiak, S.H.; Taddei, C.R.; Townley, E.R.; Wyka, B.E.J. Assoc. Off. Anal. Chem. 1981,64 (4), 864–869.Google Scholar
  3. [3]
    Zegarelli, D.J.Otolaryngol. Clin. North. Am. 1993,26 (6), 1069–1089.Google Scholar
  4. [4]
    Kang, S.H.; Kim, H.J. Pharm. Biomed. Anal. 1997,15, 1359–1364.CrossRefGoogle Scholar
  5. [5]
    Kreuz, M.D.; Howard, A.L.; Ip, D.J. Pharm. Biomed. Anal. 1999,19, 725–735.CrossRefGoogle Scholar
  6. [6]
    United States Pharmacopoeia XXIV, The United States Pharmacopeial Convention, Inc., Rockville, MD,2000.Google Scholar
  7. [7]
    Khashaba, P.Y.; El-Shabouri, S.R.; Emara, K.M.; Mohamed, A.M.J. Pharm. Biomed. Anal. 2000,22 (2), 363–376.CrossRefGoogle Scholar
  8. [8]
    Abdelmageed, O.H.; Khashaba, P.Y.Talanta 1993,40 (8), 1289–1294.CrossRefGoogle Scholar
  9. [9]
    Bedair, M.M.; Korany, M.A.; Elsayed, M.H.; Fahmy, O.T.J. Assoc. Off. Anal. Chem. 1989,72 (3), 432–435.Google Scholar
  10. [10]
    Bonazzi, D.; Cavrini, V.; Gatti, R.; Boselli, E.; Caboni, M.J. Pharm. Biomed. Anal. 1998,18 (1–2), 235–240.CrossRefGoogle Scholar
  11. [11]
    Indrayanto, G.; Aditama, L.; Tanudjaja, W.; Widjaja, S.J. Planar. Chromatogr. Mod. TLC 1998,11 (3), 201–204.Google Scholar
  12. [12]
    Arranz, A.; Echerarria, C.; Moreda, J.M.; Cid, A.; Arranz, J.F.J. Chromatogr. A 2000,871 (1–2), 399–402.CrossRefGoogle Scholar
  13. [13]
    del-Fabro, B.; Kacic, N.; Prosek, M.J. Planar. Chromatogr. Mod. TLC 1997,10 (3), 178–181.Google Scholar
  14. [14]
    Zhu, J.; Coscolluella, C.J. Chromatogr. B Biomed. Appl. 2000,741 (1), 55–65.CrossRefGoogle Scholar
  15. [15]
    Lin, M.; Wu, N.J. Pharm. Biomed. Anal. 1999,19, 945–954.CrossRefGoogle Scholar
  16. [16]
    Di-Pietra, A.M.; Andrisano, V.; Gotti, R.; Cavrini, V.J. Pharm. Biomed. Anal. 1996,14 (8–10), 1191–1199.CrossRefGoogle Scholar
  17. [17]
    Kollmorgen, D.; Kraut, B.J. Chromatogr. B 1998,707, 181–187.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 2002

Authors and Affiliations

  • P. Solich
    • 1
  • R. Hájková
    • 1
  • M. Pospíšilová
    • 1
  • J. Šícha
    • 2
  1. 1.Department of Analytical Chemistry, Faculty of PharmacyCharles UniversityHradec KrálovéCzech Republic
  2. 2.Bochemie GroupHerbacos-Bofarma LtdPardubiceCzech Republic

Personalised recommendations